

1fw

PIPER RUDNICK LLP
1200 NINETEENTH STREET, NW
WASHINGTON, DC 20036-2412
TELEPHONE: 202-861-3900
FACSIMILE: 202-223-2085

DOCKET NO.: 3802-090-27 CIP

ASSISTANT COMMISSIONER FOR PATENTS
PO BOX 1450
ALEXANDRIA, VA 22313-1450

Re: Serial No.: 10/807,449
Applicant(s): Karin JOOSS, et al.
Filing Date: March 24, 2004
For: CYTOKINE-EXPRESSING CELLULAR VACCINE COMBINATIONS
Group Art Unit: 1632
Examiner:

SIR:


Attached hereto for filing are the following papers:

Information Disclosure Statement
PTO-1449
Cited Documents (7)

Our check in the amount of \$0.00 is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary extension of time to make the filing of the attached documents timely, please charge or credit the difference to Deposit Account No. 50-1442. Further, if these papers are not considered timely filed, then a request is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

PIPER RUDNICK LLP


Steven B. Kelber
Attorney of Record
Registration No.: 30,073

Ping Wang
Registration No.: 48,328

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION: Karin JOOSS, et al.

GROUP ART UNIT: 1632

SERIAL NUMBER: 10/807,449

EXAMINER:

FILED: March 24, 2004

FOR: CYTOKINE-EXPRESSING CELLULAR COMBINATIONS

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.97

Assistant Commissioner for Patents
 PO BOX 1450
 ALEXANDRIA, VA 22313-1450

Sir:

Applicant(s) wish(es) to disclose the following information.

REFERENCES

Applicant(s) wish(es) to make of record the documents listed on the attached Form PTO-1449. Copies of the listed documents are attached, where required, as are either statements of relevancy or any readily available full or partial English translations of any non-English-language documents.

RELATED CASES

Attached is a list of Applicant's(s') pending applications and issued patents which may be related to the present application. Copies of the documents, where required, are attached along with Form PTO-1449.

CERTIFICATION

The undersigned certifies that

each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign or international patent office in a counterpart foreign or international application for the first time (to the knowledge of the undersigned, having made reasonable inquiry) not more than three months prior to the filing of this statement.

no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign or international patent office in a counterpart foreign or international application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this statement.

BASIS FOR CONSIDERATION

This Information Disclosure Statement is filed:

without fee and within three months of the filing date of the application.

without fee and within three months of the date of entry of the U.S. national stage.

without fee and before the mailing date of a first Office Action on the merits (to the knowledge of the undersigned).

without fee and with the appropriate certification above.

without fee and with a new CPA application.

without fee and with a Request for Continued Examination.

with fee and before the mailing date of any Final Office Action, Notice of Allowance or an action that otherwise closes prosecution (to the knowledge of the undersigned).

with fee, appropriate certification above, and before payment of the Issue Fee.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to Deposit Account No. 50-1442.

Respectfully submitted,
 PIPER RUDNICK LLP

Steven B. Kelber
 Attorney of Record
 Registration No. 30,073
 Ping Wang
 Registration No. 48,328

1200 Nineteenth Street, N.W.
 Washington, DC 20036-2412
 Telephone No. (202) 861-3900
 Facsimile No. (202) 223-2085

Form PTO 1449 (Modified)  LIST OF REFERENCES CITED BY APPLICANT (Use Several Sheets if Necessary)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	DOCKET NO. 3802-090-27 CIP	SERIAL NO. 10/807,449
	APPLICANT	Karin JOOSS, et al.	
	FILING DATE	March 24, 2004	
		GROUP ART UNIT 1632	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA	2004/0121300	06/24/04	FREY, et al.			
	AB	2002/0037282	03/28/02	LEVITSKY, et al.			
	AC						
	AD						
	AE						
	AF						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO
	AK				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	AP	Armitage, "Emerging Applications of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor", Blood, Vol. 92, No. 12, pp. 4491-4508, 1998.
	AQ	Armstrong, et al., "Antitumor Effects of Granulocyte-Macrophage Colony-Stimulating Factor Production by Melanoma Cells", Cancer Research, Vol. 56, pp. 2191-2198, 1996.
	AR	Dong, et al., "Angiostatin-mediated Suppression of Cancer Metastases by Primary Neoplasms Engineered to Produce Granulocyte/Macrophage Colony-stimulating Factor", Jour. Exp. Med., Vol. 188, No. 4, pp. 755-763, 1998.
	AS	Emens, et al., "Chemotherapy: Friend or foe to cancer vaccines?", Current Opinion in Molecular Therapeutics, Vol. 3, No. 1, pp. 77-84, 2001.
	AT	Jaffee, et al., "Use of Murine Models of Cytokine-Secreting Tumor Vaccines to Study Feasibility and Toxicity Issues Critical to Designing Clinical Trials", Jour. of Immunotherapy, Vol. 18, No. 1, pp. 1-9, 1995.

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.